



Novartis India Limited
Registered Office:
Inspire BKC
7th Floor
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

September 30, 2023

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

Scrip code: 500672

Dear Sir/ Madam,

Sub.: Intimation of meeting of the Board of Directors of Novartis India Limited (“the Company”) and Closure of Trading Window

This is to inform that pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of the Board of Directors of the Company is scheduled to be held on Friday, October 27, 2023, to *inter alia*, consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023.

In this connection, please note that pursuant to the ‘Code of Conduct to regulate, monitor and report share trading by Designated Persons and their immediate relatives’ (‘Code’) read with the applicable provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the Trading Window for dealing in shares of the Company by Designated Persons will be closed with effect from Sunday, October 1, 2023 to Sunday, October 29, 2023 (both days inclusive).

You are requested to take note of the above information.

Thanking You.

Yours Sincerely,

For Novartis India Limited

Malpani Nikhil
Digitally signed by Malpani Nikhil
DN: cn=Novartis, ou=People,
ou=GR, serialNumber=3079258, cn=Malpani
Nikhil
Date: 2023.09.30 08:59:44 +05'30'

Nikhil Malpani
Company Secretary and Compliance Officer